Original Article

You have full text access to this OnlineOpen article

Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1†

  1. Jorg B. Engel M.D.1,2,
  2. Andrew V. Schally Ph.D., M.D.1,2,‡,*,
  3. Gabor Halmos Ph.D.1,2,
  4. Ben Baker B.S.1,2,
  5. Attila Nagy Ph.D.1,2,
  6. Gunhild Keller M.D.1,2

Article first published online: 26 JUL 2005

DOI: 10.1002/cncr.21327

Issue

Cancer

Cancer

Volume 104, Issue 6, pages 1312–1321, 15 September 2005

Additional Information

How to Cite

Engel, J. B., Schally, A. V., Halmos, G., Baker, B., Nagy, A. and Keller, G. (2005), Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer, 104: 1312–1321. doi: 10.1002/cncr.21327

Author Information

  1. 1

    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana

  2. 2

    Section of Experimental Medicine, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana

  1. ‡

    Fax: (504) 566-1625

*VA Medical Center, 1601 Perdido Street, New Orleans, LA 70112-1262

  1. †

    The current study is dedicated to the late Ana-Maria Comaru-Schally, M.D., who died recently of thyroid carcinoma, for her intellectual, spiritual and personal contribution and for the inspiration she provided to this project.

Publication History

  1. Issue published online: 31 AUG 2005
  2. Article first published online: 26 JUL 2005
  3. Manuscript Accepted: 4 APR 2005
  4. Manuscript Revised: 23 MAR 2005
  5. Manuscript Received: 22 FEB 2005

Funded by

  • Medical Research Service of the Veterans Affairs Department
  • ZENTARIS Gmbh (Frankfurt am Main, Germany)
  • German Academic Exchange Service (DAAD)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (215K)

REFERENCES

  • 1
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2003; 55: 10–30.
    Direct Link:
  • 2
    Bristow RE. Endometrial cancer. Curr Opin Oncol. 1999; 11: 388–393.
  • 3
    Chen LM, McGonigle KF, Berek JS. Endometrial cancer: recent developments in evaluation and treatment. Oncology (Huntingt). 1999; 13: 1665–1670; discussion, 1675–1678, 1681–1682.
  • 4
    Creasman WT. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol. 1997; 24: S1–140–S1–50.
  • 5
    Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. J Epidemiol Biostat. 2001; 6: 47–86.
  • 6
    Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol. 1984; 17: 85–103.
  • 7
    Magrath IT. Targeted approaches to cancer therapy. Int J Cancer. 1994; 56: 163–166.
    Direct Link:
  • 8
    Begent RH. UICC/CRC conference on targeted cancer therapy. Royal Free Hospital School of Medicine, London, December 17-19, 1991. Int J Cancer. 1993; 55: 355–358.
    Direct Link:
  • 9
    Abou-Jawde R, Choueiri T, Alemany C, Mekhail T. An overview of targeted treatments in cancer. Clin Ther. 2003; 25: 2121–2137.
  • 10
    Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother. 2003; 52: 328–337.
  • 11
    Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol. 1999; 141: 1–14.
  • 12
    Nagy A, Armatis P, Schally AV. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci USA. 1996; 93: 2464–2469.
  • 13
    Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci. 2003; 72: 2305–2320.
  • 14
    Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab. 2004; 15: 300–310.
  • 15
    Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993; 20: 716–731.
  • 16
    Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998; 351: 417–418.
  • 17
    Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med. 1995; 25: 272–278.
  • 18
    Schally AV, Comaru-Schally AM, Nagy A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol. 2001; 22: 248–291.
  • 19
    Nagy A, Schally AV, Halmos G, et al. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA. 1998; 95: 1794–1799.
  • 20
    Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res. 1998; 58: 4132–4137.
  • 21
    Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res. 1999; 59: 1947–1953.
  • 22
    Kahan Z, Nagy A, Schally AV, et al. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Int J Cancer. 1999; 82: 592–598.
    Direct Link:
  • 23
    Kiaris H, Schally AV, Nagy A, Sun B, Szepeshazi K, Halmos G. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Clin Cancer Res. 2000; 6: 709–717.
  • 24
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res. 2003; 9: 4505–4513.
  • 25
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238. J Urol. 2004; 171: 911–915.
  • 26
    Denzler B, Reubi JC. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer. 1999; 85: 188–198.
    Direct Link:
  • 27
    Schulz S, Schmitt J, Weise W. Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. Gynecol Oncol. 2003; 89: 385–390.
  • 28
    Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976; 455: 152–162.
  • 29
    Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992; 258: 1650–1654.
  • 30
    Ross DD, Yang W, Abruzzo LV, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 1999; 91: 429–433.
  • 31
    Schneider J, Efferth T, Centeno MM, Mattern J, Rodriguez-Escudero FJ, Volm M. High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue. Eur J Cancer. 1993; 29A: 554–558.
  • 32
    Schneider J, Efferth T, Rodriguez-Escudero FJ, Volm M. Intrinsic overexpression of two different mechanisms of resistance to chemotherapy (P-glycoprotein and GST-pi) in human endometrial carcinoma. Chemotherapy. 1994; 40: 265–271.
  • 33
    Esteller M, Martinez-Palones JM, Garcia A, Xercavins J, Reventos J. High rate of MDR-1 and heterogeneous pattern of MRP expression without gene amplification in endometrial cancer. Int J Cancer. 1995; 63: 798–803.
    Direct Link:
  • 34
    Koshiyama M, Yoshida M, Fujii H, et al. Expression of multidrug resistance-associated protein in endometrial carcinomas: correlation with clinicopathology and prognosis. Ann Diagn Pathol. 1999; 3: 81–87.
  • 35
    Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci USA. 1986; 83: 1896–1900.
  • 36
    Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol. 1972; 114: 1012–1019.
  • 37
    Way DL, Grosso DS, Davis JR, Surwit EA, Christian CD. Characterization of a new human endometrial carcinoma (RL95–2) established in tissue culture. In Vitro. 1983; 19: 147–158.
  • 38
    Dawe CJ, Banfield WG, Morgan WD, Slatick MS, Curth HO. Growth in continuous culture, and in hamsters, of cells from a neoplasm associated with Acanthosis nigricans. J Natl Cancer Inst. 1964; 33: 441–456.
  • 39
    Halmos G, Sun B, Schally AV, Hebert F, Nagy A. Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab. 2000; 85: 3509–3512.
  • 40
    Bajo AM, Schally AV, Halmos G, Nagy A. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res. 2003; 9: 3742–3748.
  • 41
    Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, Szepeshazi K. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc Natl Acad Sci USA. 2002; 99: 3836–3841.
  • 42
    Szepeshazi K, Schally AV, Nagy A, Wagner BW, Bajo AM, Halmos G. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer. 2003; 98: 1401–1410.
    Direct Link:
  • 43
    Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab. 2000; 85: 2564–2571.
  • 44
    Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980; 107: 220–239.
  • 45
    Rasmussen R. Quantification on the LightCycler. In: MeuerSWC, NakagawaraK, editors. Rapid cycle real-time PCR, methods and applications. Heidelberg: Springer Press, 2001: 21–34.
  • 46
    Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: 2003–7.
  • 47
    Grundker C, Volker P, Griesinger F, et al. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol. 2002; 187: 528–537.
  • 48
    Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G. Effective treatment of experimental human endometrial cancers with targeted cytotoxic LHRH-analogs AN-152 and AN-207. Fertil Steril. 83: 1125–33.
  • 49
    Mishima M, Yano T, Jimbo H, et al. Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. Am J Obstet Gynecol. 1999; 81: 583–590.
  • 50
    Plonowski A, Schally AV, Koppan M, et al. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer. 2001; 92: 1168–1176.
    Direct Link:
  • 51
    Reubi JC, Waser B, van Hagen M, et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer. 1992; 50: 895–900.
    Direct Link:
  • 52
    Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med. 1998; 217: 143–152.
  • 53
    McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ, Anthony LB. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am. 1998; 4: 94–102.
  • 54
    Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. Int J Cancer. 2000; 88: 652–657.
    Direct Link:
  • 55
    Nagy A, Plonowski A, Schally AV. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proc Natl Acad Sci USA. 2000; 97: 829–834.
  • 56
    Gunthert AR, Grundker C, Bongertz T, et al. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol. 2004; 191: 1164–1172.
View Full Article (HTML) Get PDF (215K)